Pyxis Oncology Closes $102.8M Offering with Warrants, Extends Cash Runway into H1 2028
PYXS has more than doubled off its 52-week low of $1.03 on elevated volume (2.1× avg).
Summary
Pyxis Oncology closed a public offering, raising $102.8 million in net proceeds through shares and warrants, extending its cash runway into the first half of 2028, though with significant potential dilution. GordonMD Global Investments and related entities acquired 13,063,766 shares and 7,546,766 common warrants in the offering at a combined price of $2.90 per share and warrant.
Updated with an SEC 4 filing · What changed
Updates
· SEC 4 — GordonMD Global Investments and related entities acquired 13,063,766 shares and 7,546,766 common warrants in the offering at a combined price of $2.90 per share and warrant.
Key Events · Financing and Capital Events · PYXS
-
New · · SEC 4
GordonMD Global Investments Acquires Shares and Warrants
GordonMD Global Investments and related entities acquired 13,063,766 shares and 7,546,766 common warrants in the offering at a combined price of $2.90 per share and warrant.
-
Public Offering Closed
Pyxis Oncology closed an underwritten public offering on October 1, 2026, raising approximately $102.8 million in net proceeds after deducting underwriting discounts and expenses.
-
Equity and Warrants Issued
The offering included 36,047,919 shares of common stock, 1,883,121 pre-funded warrants (exercisable at $0.001), and accompanying common warrants to purchase up to 49,310,352 shares (exercisable at $3.50). Each share or pre-funded warrant was sold with 1.3 common warrants.
-
Significant Potential Dilution
The offering, including pre-funded warrants, represents an immediate increase of approximately 45.7% to the estimated outstanding shares. If all common warrants are exercised, total potential dilution could exceed 100% of the estimated current outstanding shares.
-
Extended Cash Runway
The net proceeds, combined with existing cash and cash equivalents, are expected to fund the company's operating expenses and capital expenditure requirements into the first half of 2028, addressing previous going concern warnings.
Analysis · PYXS · Life Sciences
Pyxis Oncology has closed a significant public offering, raising $102.8 million in net proceeds. This capital infusion is critical for the company, extending its cash runway into the first half of 2028 and directly addressing the previously disclosed going concern warning. The offering included a substantial number of shares and warrants, leading to significant potential dilution for existing shareholders. While the immediate issuance of shares and pre-funded warrants represents an approximate 45.7% increase to the estimated outstanding shares, the full exercise of all common warrants could lead to over 100% dilution. The common warrants' exercisability is contingent on shareholder approval to increase authorized shares, which the company has committed to seeking. The offering was priced at $2.90 per unit (share plus warrant), which was a premium to the stock's price at the time of this report, indicating institutional confidence in the company's prospects despite the dilutive nature of the raise. GordonMD Global Investments and related entities acquired 13,063,766 shares and 7,546,766 common warrants in the offering at a combined price of $2.90 per share and warrant.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.6% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $2.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.7M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.